Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Forecasted Market Size of the Dupuytren's Disease Market by 2029?
The dupuytren's disease market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.51 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to a growing aging population, increasing genetic predisposition, increasing prevalence of diabetes, rising alcohol consumption, and increasing manual labor and repetitive hand trauma.
The dupuytren's disease market size is expected to see strong growth in the next few years. It will grow to " $5.62 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing advancements in treatment options, increasing awareness and early diagnosis, growing healthcare expenditure, rising adoption of minimally invasive procedures, and expanding research and development activities. Major trends in the forecast period include advancements in gene therapy, advancements in regenerative medicine and stem cell therapy, innovation in AI-driven diagnostic tools, advancement in 3D printing for custom orthotics, and innovation in minimally invasive surgical techniques.
Get your free report sample today:
What Are the Major Growth Drivers for the Dupuytren's Disease Market?
The rising minimally invasive treatments are expected to propel the growth of the dupuytren’s disease market going forward. Minimally invasive treatments are medical procedures performed with minimal incisions or tissue damage, resulting in pain relief, and reduced scarring. People are increasingly opting for minimally invasive treatments as they allow for faster recovery with less discomfort and a significantly lower risk of complications compared to traditional surgery. Minimally invasive treatments provide effective relief for Dupuytren’s disease patients by restoring hand function, reducing contracture, and ensuring a quicker, more comfortable recovery. For instance, in June 2023, according to a report published by the Royal Australasian College of Surgeons (RACS), an Australia-based government organization, there is a 12% rise in procedures performed using da Vinci platforms, increasing from 17,852 in 2021 to 19,989 in 2022 in Australia. Therefore, the rising minimally invasive treatments are a key factor driving the expansion of the dupuytren’s disease market.
Which Key Segments Are Included in the Dupuytren's Disease Market Analysis?
The dupuytren's diseasemarket covered in this report is segmented –
1) By Disease Type: Type I; Type II; Type III
2) By Treatment: Surgery; Radiation Therapy; Needle Aponeurotomy; Steroid Shot; Enzyme Injection; Occupational Therapy; Other Treatments
3) By Route of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Diagnosis: Physical Examination; X-Ray; Other Diagnosis
5) By End-User: Hospitals; Clinics; Academic And Research Institute; Other End-Users
Subsegments:
1) By Type I: Classical Dupuytren’s Disease; Familial Dupuytren’s Disease
2) By Type II: Palmar Fasciitis; Ledderhose Disease
3) By Type III: Garrod’s Pads; Peyronie’s Disease
What Are the Most Prominent Trends Impacting the Dupuytren's Disease Market?
Major companies operating in the dupuytren's disease market are focusing on clinical trials to develop novel, first-line, disease-modifying treatment options. Clinical trials are research studies that evaluate the safety, effectiveness, and potential side effects of new medical treatments, drugs, or procedures in human participants before they are approved for widespread use. For instance, in April 2023, Ventoux Biosciences, a US-based biopharmaceutical company specializing in developing non-surgical therapies for Dupuytren's diseases announced positive pre-clinical results for its fibrosis treatment, specifically targeting Dupuytren’s contracture, a condition affecting about five percent of the U.S. population. The company's lead candidate, VEN-201, is a repurposed commercially available drug that has shown efficacy in reducing skin fibrosis in mice models. This breakthrough has prompted Ventoux to initiate a fundraising round to advance the development of VEN-201.
Who Are the Leading Market Participants in the Dupuytren's Disease Market?
Major companies operating in the dupuytren's disease market are Pfizer Inc., Aetna Inc., Mayo clinic, Penn Medicine, Mercy Health, Endo Inc., Resilience Orthopedics, Raleigh Orthopaedic, Hoag Orthopedic Institute, OSS Health, Connext Inc., University of Utah Health, Ventoux Biosciences Inc., Auxilium Pharmaceuticals, 180 Life Sciences Corp., Brigid Freyne MD, Nantong Jinghua Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Actiza Pharmaceutical Private Limited, Spear Pharmaceuticals
Get the detailed dupuytren's disease market report today
Which Regions Are Driving the Highest Demand in the Dupuytren's Disease Market?
North America was the largest region in the dupuytren's disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dupuytren's disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment